Grants per year
Personal profile
Research Interests
My clinical practice involves the medical treatment of breast cancer in women and men with a particular interest in young women with breast cancer. My clinical research endeavors involve chemotherapy, endocrine therapy, and novel therapies for the treatment of breast cancer. I am interested in ways to optimize and individualize breast cancer treatment based on patient characteristics as well as tumor specific molecular profiles.
Certifications and Licenses
| Medical Oncology | |
| Hematology |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Georgetown University
… → 1998
Research interests keywords
- Breast Cancer
- Cancer Genetics
- Cancer Survivorship
Fingerprint
Dive into the research topics where Lisa Ellen Flaum is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #19-188: NU DF21B07: Evaluation of Talazoparib, a PARP Inhibitor, in Patients with Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Flaum, L. E. (PD/PI), Flaum, L. E. (PD/PI), Shah, A. N. (PD/PI) & Shah, A. N. (PD/PI)
Dana-Farber/Partners CancerCare, Inc., Pfizer Inc.
7/22/22 → 7/22/28
Project: Research project
-
Prot #CBYL719C2202: EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment with Alpelisib (BYL719) in Combination with Fulves
Flaum, L. E. (PD/PI)
Novartis Pharmaceuticals Corporation
9/9/21 → 2/27/25
Project: Research project
-
Prot #17-101/NU DF17B11: Palbociclib after CDK and Endocrine Therapy (PACE): A Randomized Phase II study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
Flaum, L. E. (PD/PI) & Shah, A. N. (PD/PI)
Dana-Farber/Partners CancerCare, Inc., Pfizer Inc.
10/4/18 → 10/4/24
Project: Research project
-
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Smith, K. L., Zhao, F., Mayer, I. A., Tevaarwerk, A. J., Garcia, S. F., Arteaga, C. L., Symmans, W. F., Park, B. H., Burnette, B. L., Makower, D. F., Block, M., Morley, K. A., Jani, C. R., Mescher, C., Dewani, S. J., Brown-Glaberman, U., Flaum, L. E., Mayer, E. L., Sikov, W. M. & Rodler, E. T. & 5 others, , May 15 2024, In: cancer. 130, 10, p. 1747-1757 11 p.Research output: Contribution to journal › Article › peer-review
-
Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA
Zhang, Q., Cai, Z., Gerratana, L., Davis, A. A., D’Amico, P., Chawla, A., Jacob, S., Zhang, Y., Jiao, J., Qin, W., Reduzzi, C., Flaum, L., Shah, A. N. & Gradishar, W. J., Aug 15 2024, In: Clinical Cancer Research. 30, 16, p. 3470-3480 11 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer
Chavez-MacGregor, M., Miao, J., Pusztai, L., Goetz, M. P., Rastogi, P., Ganz, P. A., Mamounas, E. P., Paik, S., Bandos, H., Razaq, W., O'Dea, A., Kaklamani, V., Silber, A. L. M., Flaum, L. E., Andreopoulou, E., Wendt, A. G., Carney, J. F., Sharma, P., Gralow, J. R. & Lew, D. L. & 2 others, , Sep 1 2024, In: Journal of Clinical Oncology. 42, 25, p. 3012-3021 10 p.Research output: Contribution to journal › Article › peer-review
7 Scopus citations -
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
OlympiA Clinical Trial Steering Committee and Investigators, Dec 1 2022, In: Annals of Oncology. 33, 12, p. 1250-1268 19 p.Research output: Contribution to journal › Article › peer-review
283 Scopus citations -
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer
Gerratana, L., Davis, A. A., Zhang, Q., Basile, D., Rossi, G., Strickland, K., Franzoni, A., Allegri, L., Mu, Z., Zhang, Y., Flaum, L. E., Damante, G., Gradishar, W. J., Platanias, L. C., Behdad, A., Yang, H., Puglisi, F. & Cristofanilli, M., 2021, In: JCO Precision Oncology. 5, p. 943-952 10 p.Research output: Contribution to journal › Article › peer-review
Open Access37 Scopus citations
Datasets
-
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer
Davis, A. A. (Creator), Zhang, Q. (Creator), Gerratana, L. (Creator), Shah, A. N. (Creator), Zhan, Y. (Creator), Qiang, W. (Creator), Finkelman, B. S. (Creator), Flaum, L. (Creator), Behdad, A. (Creator), Gradishar, W. J. (Creator), Platanias, L. C. (Creator) & Cristofanilli, M. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4770416, https://springernature.figshare.com/collections/Association_of_a_novel_circulating_tumor_DNA_next-generating_sequencing_platform_with_circulating_tumor_cells_CTCs_and_CTC_clusters_in_metastatic_breast_cancer/4770416
Dataset